688266 泽璟制药
已收盘 12-31 15:00:00
资讯
新帖
简况
每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款
证券之星 · 01-02
每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款
泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款
美股速递 · 2025-12-31
泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款
泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化
美股速递 · 2025-12-31
泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化
泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议
智通财经 · 2025-12-31
泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议
每周股票复盘：泽璟制药（688266）递交H股上市申请
证券之星 · 2025-12-28
每周股票复盘：泽璟制药（688266）递交H股上市申请
泽璟制药递表港交所 拥有三款已上市药物
智通财经 · 2025-12-22
泽璟制药递表港交所 拥有三款已上市药物
新股消息 | 泽璟制药(688266.SH)递表港交所
智通财经 · 2025-12-21
新股消息 | 泽璟制药(688266.SH)递表港交所
21股获推荐，泽璟制药、佐力药业目标价涨幅超30%
21世纪经济报道 · 2025-12-16
21股获推荐，泽璟制药、佐力药业目标价涨幅超30%
泽璟制药（688266）披露拟发行H股并在港交所上市，12月12日股价上涨0.97%
证券之星 · 2025-12-12
泽璟制药（688266）披露拟发行H股并在港交所上市，12月12日股价上涨0.97%
泽璟制药：盐酸吉卡昔替尼片纳入2025年国家医保药品目录
证券之星 · 2025-12-07
泽璟制药：盐酸吉卡昔替尼片纳入2025年国家医保药品目录
泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%
证券之星 · 2025-12-02
泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%
泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单
智通财经 · 2025-11-24
泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单
泽璟制药计划寻求在香港上市
投资观察 · 2025-11-20
泽璟制药计划寻求在香港上市
泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准
智通财经 · 2025-11-18
泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准
泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌
美股速递 · 2025-11-16
泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌
泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定
智通财经 · 2025-11-16
泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定
泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市
智通财经 · 2025-11-14
泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市
泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准
智通财经 · 2025-11-13
泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准
【机构调研记录】红塔红土调研泽璟制药
证券之星 · 2025-11-11
【机构调研记录】红塔红土调研泽璟制药
【机构调研记录】格林基金调研泽璟制药
证券之星 · 2025-11-11
【机构调研记录】格林基金调研泽璟制药
加载更多
公司概况
公司名称：
苏州泽璟生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2020-01-23
主营业务：
苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。
发行价格：
33.76
{"stockData":{"symbol":"688266","market":"SH","secType":"STK","nameCN":"泽璟制药","latestPrice":92.7,"timestamp":1767164400000,"preClose":92.25,"halted":0,"volume":2250150,"delay":0,"changeRate":0.0049,"floatShares":265000000,"shares":265000000,"eps":-0.5038,"marketStatus":"已收盘","change":0.45,"latestTime":"12-31 15:00:00","open":92.24,"high":93.99,"low":90.03,"amount":208000000,"amplitude":0.0429,"askPrice":92.7,"askSize":7,"bidPrice":92.6,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-0.5038,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"adjPreClose":92.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767144600000,1767151800000],[1767157200000,1767164400000]],"highLimit":101.48,"lowLimit":83.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":264708186,"isCdr":false,"pbRate":21.36,"roa":"--","roe":"--","epsLYR":-0.52,"committee":0.714286,"marketValue":24538000000,"turnoverRate":0.0085,"status":0,"afterMarket":{"amount":0,"volume":0,"close":92.7,"buyVolume":0,"sellVolume":0,"time":1767166437558,"indexStatus":"已收盘 12-31 15:30:00","preClose":92.25},"floatMarketCap":24538000000},"requestUrl":"/m/hq/s/688266","defaultTab":"news","newsList":[{"id":"2600035009","title":"每周股票复盘：泽璟制药（688266）获艾伯维1亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2600035009","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600035009?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:24","pubTimestamp":1767291851,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，泽璟制药报收于99.53元，较上周的101.33元下跌1.78%。本周关注点公司公告汇总：泽璟制药与艾伯维就ZG006达成全球合作，获1亿美元首付款。公司公告汇总：艾伯维可支付泽璟制药最高达10.75亿美元的里程碑款项。泽璟将获得1亿美元首付款，以及最高6000万美元的近期里程碑及许可选择相关付款；若艾伯维行使许可选择权，泽璟还可获得最高10.75亿美元里程碑付款，并享有海外净销售额的阶梯式特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"1165741365","title":"泽璟制药与艾伯维达成许可协议 有望获1亿美元首付款及11亿美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1165741365","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165741365?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:31","pubTimestamp":1767173475,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，若合作方艾伯维公司行使许可选择权，公司将获得1亿美元的首付款，并有资格获得最高达11亿美元的里程碑付款。此次合作涉及特定创新药物的授权许可，彰显了泽璟制药研发实力的国际认可。协议具体条款将根据研发进展分阶段触发付款条件，为泽璟制药带来长期现金流支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0553294199.USD","LU1496350171.SGD","LU2023251221.USD","LU0738911758.USD","LU0985320562.USD","IE00BLSP4452.SGD","LU0158827948.USD","LU2237443465.HKD","BK4139","IE00BVYPNW00.USD","BK4550","LU0256863811.USD","LU0310799852.SGD","SG9999001440.SGD","SG9999011175.SGD","LU0320765646.SGD","LU2089283258.USD","LU1585245621.USD","LU0820561909.HKD","SG9999015952.SGD","LU1732799900.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU1244550577.SGD","IE00BN8TJ469.HKD","LU0256863902.USD","LU0456855351.SGD","LU2237443895.HKD","LU0170899867.USD","LU1093756168.USD","BK4559","LU2133065610.SGD","ABBV","LU1003077747.HKD","LU0417517546.SGD","IE00BDGV0183.EUR","LU1093756325.SGD","IE00BLSP4239.USD","LU1291159041.SGD","IE00BSNM7G36.USD","LU0124676726.USD","LU0861579265.USD","LU2129689514.USD","LU1551013342.USD","BK4566","LU1551013425.SGD","LU1934455277.USD","LU0211328371.USD","LU2237443549.SGD","LU0310800379.SGD","LU0198837287.USD","IE00B19Z3581.USD","IE00BJJMRZ35.SGD","SG9999015945.SGD","LU2087621335.USD","IE00BVYPNV92.GBP","LU2112291526.USD","IE00BGHQF631.EUR","LU0289739699.SGD","IE0002141913.USD","IE00B3PB1722.GBP","688266","LU0211327993.USD","LU0912757837.SGD","LU1037948541.HKD","LU0661504455.SGD","BK4533","IE00BJT1NW94.SGD","LU2468319806.SGD","BK4585","IE00B4R5TH58.HKD","LU0234570918.USD","LU1929549753.HKD","LU1839511570.USD","LU1989771016.USD","IE0004445239.USD","LU1983299246.USD","LU0795875086.SGD","LU1061106388.HKD","IE00BBT3K403.USD","LU0689626769.HKD","LU1267930573.SGD","LU0114720955.EUR","IE0002270589.USD","LU2089284900.SGD","LU2347655156.SGD","LU2129689605.HKD","LU1074936037.SGD","BK4588","LU1934455194.USD","LU0203347892.USD","LU0545039389.USD","LU2237443382.USD","BK4534","LU2237443978.SGD","LU0820561818.USD","LU1732800096.USD","LU0203345920.USD","IE00B2B36J28.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","IE00B42XCP33.USD","LU0708994859.HKD","LU1162221912.USD","LU1718418525.SGD","LU1244550221.USD","LU2237443622.USD","LU1496350502.SGD","LU1989772923.USD","LU0128525929.USD","LU0029864427.USD","LU1023059063.AUD","BK0239","LU1057294990.SGD","LU1244550494.USD","LU2089984988.USD","LU0432979614.USD","LU0234572021.USD","LU0943347566.SGD","LU2129689431.USD","LU0795875169.SGD","LU0689472784.USD","LU0949170772.SGD","SG9999003800.SGD","SG9999015986.USD","LU0122379950.USD","LU0098860793.USD","LU0882574055.USD","BK4581","LU1989772840.SGD","LU1934455863.HKD","LU0965509101.SGD","LU1037948897.HKD","LU0965509283.SGD","LU1267930490.SGD","SG9999015978.USD","LU0965508806.USD","LU0965509010.AUD","LU0058720904.USD"],"gpt_icon":0},{"id":"1177773699","title":"泽璟制药与艾伯维就阿尔维塔米格达成战略合作，共同推进研发与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1177773699","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177773699?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:31","pubTimestamp":1767173473,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，已与艾伯维公司签署一项战略合作协议，双方将就阿尔维塔米格的开发及商业化展开深度合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0949170772.SGD","LU1037948541.HKD","LU0124676726.USD","LU2089284900.SGD","LU0661504455.SGD","LU2089984988.USD","LU0417517546.SGD","LU1551013342.USD","LU1934455863.HKD","LU0738911758.USD","LU2129689514.USD","LU0965509101.SGD","SG9999015978.USD","688266","LU0211327993.USD","LU0234570918.USD","LU1732800096.USD","LU0310800379.SGD","IE00B2B36J28.USD","SG9999001440.SGD","LU0912757837.SGD","IE0002270589.USD","LU2237443978.SGD","LU1061106388.HKD","BK4139","LU0320765646.SGD","LU2237443465.HKD","LU1929549753.HKD","LU0456855351.SGD","LU1989772840.SGD","LU2129689605.HKD","LU0203347892.USD","IE00BVYPNW00.USD","LU0128525929.USD","IE00BLSP4239.USD","LU2468319806.SGD","LU1003077747.HKD","LU1267930573.SGD","SG9999003800.SGD","LU1983299246.USD","LU0158827948.USD","LU2087621335.USD","LU1037948897.HKD","LU0058720904.USD","LU0708994859.HKD","LU1162221912.USD","LU1732799900.SGD","LU0795875086.SGD","LU0122379950.USD","LU1934455277.USD","IE00B3PB1722.GBP","LU0432979614.USD","LU2129689431.USD","LU0310799852.SGD","LU0965509010.AUD","LU1023059063.AUD","LU1839511570.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU0965509283.SGD","LU0211328371.USD","LU0689472784.USD","SG9999015986.USD","LU1244550221.USD","IE00BDGV0183.EUR","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU2237443549.SGD","LU0820561818.USD","SG9999015945.SGD","IE00BLSP4452.SGD","IE0004445239.USD","BK4559","LU0029864427.USD","LU0545039389.USD","LU1430594728.SGD","LU2237443622.USD","ABBV","BK4533","BK4566","IE00BFTCPJ56.SGD","LU2347655156.SGD","LU1718418525.SGD","LU0965508806.USD","BK4534","LU1496350502.SGD","IE00B19Z3B42.SGD","IE00BN8TJ469.HKD","LU1244550577.SGD","BK0239","LU2023251221.USD","LU1989772923.USD","LU2133065610.SGD","SG9999011175.SGD","LU1244550494.USD","LU0820561909.HKD","BK4550","LU1093756325.SGD","IE0002141913.USD","IE00BGHQF631.EUR","LU0795875169.SGD","LU1291159041.SGD","LU0256863811.USD","IE00BBT3K403.USD","LU1093756168.USD","LU1496350171.SGD","LU2237443382.USD","SG9999015952.SGD","LU1551013425.SGD","LU1934455194.USD","LU2089283258.USD","LU0553294199.USD","LU0943347566.SGD","LU1074936037.SGD","IE00B19Z3581.USD","LU1267930490.SGD","LU0861579265.USD","LU0198837287.USD","LU0234572021.USD","LU1585245621.USD","IE00B4R5TH58.HKD","BK4585","LU1057294990.SGD","BK4581","BK4588","LU2112291526.USD","LU0882574055.USD","IE00B42XCP33.USD","LU0170899867.USD","IE00BVYPNV92.GBP","LU0289739699.SGD","LU0985320562.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2237443895.HKD","LU0098860793.USD","LU0203345920.USD","LU0689626769.HKD","LU0256863902.USD"],"gpt_icon":0},{"id":"2595724052","title":"泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595724052","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595724052?lang=zh_cn&edition=full","pubTime":"2025-12-31 16:27","pubTimestamp":1767169654,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司与艾伯维集团控股公司就ZG006的全球开发及商业化达成战略合作与许可选择权协议。根据协议，艾伯维获得ZG006在大中华区以外地区独家开发与商业化权利，而泽璟将保留在大中华区ZG006的开发与商业化权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)与艾伯维就ZG006的开发和商业化权益达成全球战略合作与许可选择权协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2594440432","title":"每周股票复盘：泽璟制药（688266）递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2594440432","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594440432?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:28","pubTimestamp":1766863692,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，泽璟制药报收于99.53元，较上周的101.33元下跌1.78%。本周，泽璟制药12月25日盘中最高价报103.4元。泽璟制药当前最新总市值263.46亿元，在化学制药板块市值排名17/151，在两市A股市值排名752/5178。本周关注点公司公告汇总：泽璟制药向香港联交所递交H股发行上市申请并刊发申请资料。该申请材料为按香港证监会及香港联交所要求编制的草拟版本，可能更新修订，不构成认购H股的要约或要约邀请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2593629106","title":"泽璟制药递表港交所 拥有三款已上市药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2593629106","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593629106?lang=zh_cn&edition=full","pubTime":"2025-12-22 13:32","pubTimestamp":1766381520,"startTime":"0","endTime":"0","summary":"据港交所12月19日披露，苏州泽璟生物制药股份有限公司(简称：泽璟制药)(688266.SH)向港交所主板提交上市申请，中金公司为其独家保荐人。公司简介招股书显示，泽璟制药为一家综合生物制药企 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20251222/c673393834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2593140049","title":"新股消息 | 泽璟制药(688266.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2593140049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593140049?lang=zh_cn&edition=full","pubTime":"2025-12-21 09:14","pubTimestamp":1766279665,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月19日披露，苏州泽璟生物制药股份有限公司向港交所主板提交上市申请，中金公司为其独家保荐人。泽璟制药的产品组合及管线涵盖已上市药物、后期临床候选药物及处于创新前沿的早期发现项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","HEXmain","688266"],"gpt_icon":0},{"id":"2591767248","title":"21股获推荐，泽璟制药、佐力药业目标价涨幅超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591767248","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591767248?lang=zh_cn&edition=full","pubTime":"2025-12-16 10:07","pubTimestamp":1765850820,"startTime":"0","endTime":"0","summary":"南财投研通数据显示，12月15日，券商给予上市公司目标价共6次，按最新收盘价计算，目标价涨幅排名居前的公司有泽璟制药、佐力药业、创世纪，目标价涨幅分别为35.00%、34.58%、27.40%，分别属于化学制药、中药、自动化设备行业。从券商推荐家数来看，12月15日有21家上市公司得到券商推荐，其中佐力药业获得5家推荐，天地科技、常宝股份等均获得1家推荐。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftm3311202.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-16/doc-inhayftm3311202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300181","688266"],"gpt_icon":0},{"id":"2590312502","title":"泽璟制药（688266）披露拟发行H股并在港交所上市，12月12日股价上涨0.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590312502","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590312502?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:20","pubTimestamp":1765549242,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，泽璟制药报收于109.41元，较前一交易日上涨0.97%，最新总市值为289.62亿元。近日，苏州泽璟生物制药股份有限公司召开2025年第一次临时股东会，审议通过了关于公司发行H股股票并在香港联合交易所上市的相关议案，包括上市方案、募集资金使用计划、转为境外募集股份有限公司、修订公司章程及相关制度、变更独立董事等共计13项议案，所有议案均获通过。出席会议股东所持表决权占公司总表决权的57.2087%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200041630.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688266","BK0239","HEXmain"],"gpt_icon":0},{"id":"2589767118","title":"泽璟制药：盐酸吉卡昔替尼片纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589767118","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589767118?lang=zh_cn&edition=full","pubTime":"2025-12-07 15:40","pubTimestamp":1765093230,"startTime":"0","endTime":"0","summary":"泽璟制药(688266.SH)公告称，公司自主研发的盐酸吉卡昔替尼片通过国家医保谈判，被纳入2025年国家医保药品目录，协议有效期为2026年1月1日至2027年12月31日。该药物属于1类新药，用于治疗中危或高危原发性骨髓纤维化等疾病。纳入医保目录将有助于提高药物的可负担性和可及性，推动市场推广和销售规模提升，对公司长期经营发展有积极影响，但短期内不会对经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120700002592.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2588059052","title":"泽璟制药（688266）披露拟发行H股并在港交所上市，12月2日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588059052?lang=zh_cn&edition=full","pubTime":"2025-12-02 22:27","pubTimestamp":1764685649,"startTime":"0","endTime":"0","summary":"截至2025年12月2日收盘，泽璟制药报收于106.96元，较前一交易日下跌1.7%，最新总市值为283.13亿元。根据近日发布的《泽璟制药2025年第一次临时股东会会议资料》，苏州泽璟生物制药股份有限公司拟发行H股股票并在香港联合交易所主板上市，发行规模不超过发行后总股本的25%，募集资金将用于新药研发、产能扩张及补充流动资金。公司拟转为境外募集股份有限公司，并授权董事会全权处理上市相关事宜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200039944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266","HEXmain"],"gpt_icon":0},{"id":"2585468717","title":"泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2585468717","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585468717?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:00","pubTimestamp":1763978457,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，近日，公司在研产品注射用ZG006被国家药品监督管理局药品审评中心(CDE)纳入突破性治疗品种公示名单，适应症为ZG006单药治疗既往至少经含铂方案治疗后复发或进展的DLL3阳性的晚期神经内分泌癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006治疗晚期神经内分泌癌纳入突破性治疗品种公示名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"1124974287","title":"泽璟制药计划寻求在香港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1124974287","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124974287?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:49","pubTimestamp":1763574556,"startTime":"0","endTime":"0","summary":"11月14日 - 泽璟制药（Suzhou Zelgen Biopharmaceuticals Co Ltd，股票代码：688266.SS）宣布，计划寻求在香港上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2584984363","title":"泽璟制药(688266.SH)：注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗(依托泊苷/卡铂)联用获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2584984363","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584984363?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:50","pubTimestamp":1763452203,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006与PD-1/PD-L1免疫检查点抑制剂及化疗联合用于小细胞肺癌的临床试验获得批准。ZG006 是一种针对两个不同 DLL3 表位及CD3的三特异性T细胞衔接器。临床前研究结果显示，ZG006在小鼠肿瘤模型上具有显著的肿瘤抑制作用，可以导致显著比例的小鼠肿瘤完全消退，说明ZG006 具有强效的肿瘤杀伤作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169590202.USD","BK0239","688266","BK4023","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"1172426615","title":"泽璟制药宣布其Zg006注射剂获得美国FDA的孤儿药认定，用于治疗神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1172426615","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172426615?lang=zh_cn&edition=full","pubTime":"2025-11-16 16:04","pubTimestamp":1763280251,"startTime":"0","endTime":"0","summary":"泽璟制药宣布，其Zg006注射剂已获得美国食品药品监督管理局（FDA）授予的孤儿药认定，用于治疗神经内分泌癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2583666507","title":"泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666507","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583666507?lang=zh_cn&edition=full","pubTime":"2025-11-16 15:50","pubTimestamp":1763279423,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)公告，公司在研产品注射用ZG006获得美国食品药品监督管理局(“FDA”)颁发孤儿药资格认定，用于治疗神经内分泌癌。公告提示，本次获得孤儿药资格认定后，公司仍需就注射用ZG006用于治疗神经内分泌癌的后续临床试验、注册申报方案等与FDA进行沟通与协商，最终能否成功完成临床试验、获得FDA上市许可及上市时间均具有不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006用于治疗神经内分泌癌获FDA孤儿药资格认定","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2583457181","title":"泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583457181","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583457181?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:35","pubTimestamp":1763112927,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药(688266.SH)发布公告，为满足公司国际化战略及海外业务布局需要，提升公司国际品牌知名度，增强公司综合竞争力，公司拟发行境外上市股份(H股)并申请在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369406.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)筹划发行H股股票并在香港联交所上市","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2583550238","title":"泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583550238","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583550238?lang=zh_cn&edition=full","pubTime":"2025-11-13 17:22","pubTimestamp":1763025729,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泽璟制药 发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，注射用ZG006与依托泊苷及顺铂联合用于晚期神经内分泌癌的临床试验获得批准。ZG006 是一种针对两个不同 DLL3 表位及CD3的三特异性T细胞衔接器。临床前研究结果显示，ZG006在小鼠肿瘤模型上具有显著的肿瘤抑制作用，可以导致显著比例的小鼠肿瘤完全消退，说明ZG006 具有强效的肿瘤杀伤作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368850.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"泽璟制药(688266.SH)：注射用ZG006与依托泊苷及顺铂联用获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688266","BK0239"],"gpt_icon":0},{"id":"2582781381","title":"【机构调研记录】红塔红土调研泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582781381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582781381?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:06","pubTimestamp":1762819585,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，红塔红土近期对1家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为2.05，近一年增长56.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0},{"id":"2582089381","title":"【机构调研记录】格林基金调研泽璟制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2582089381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582089381?lang=zh_cn&edition=full","pubTime":"2025-11-11 08:06","pubTimestamp":1762819566,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月10日披露的机构调研信息，格林基金近期对1家上市公司进行了调研，相关名单如下：1）泽璟制药 调研纪要：2025年前三季度，公司实现营收59,344.01万元，同比增长54.49%，主要因药品销售增长。ZGGS34获中美临床批准。格林基金成立于2016年，截至目前，资产管理规模234.14亿元，排名119/211；资产管理规模228.4亿元，排名99/211；管理公募基金数61只，排名95/211；旗下公募基金经理11人，排名104/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100004263.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688266"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767552664882,"stockEarnings":[{"period":"1week","weight":-0.0805},{"period":"1month","weight":-0.1481},{"period":"3month","weight":-0.1797},{"period":"6month","weight":-0.1983},{"period":"1year","weight":0.4877},{"period":"ytd","weight":0.4877}],"compareEarnings":[{"period":"1week","weight":0.0071},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.143},{"period":"1year","weight":0.1841},{"period":"ytd","weight":0.1841}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"苏州泽璟生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8809人(较上一季度增加0.16%)","perCapita":"30049股","listingDate":"2020-01-23","address":"江苏省苏州市昆山市玉山镇晨丰路209号","registeredCapital":"26470万元","survey":" 苏州泽璟生物制药股份有限公司的主营业务是化学新药及生物新药的研发、生产及销售。公司的主要产品是甲苯磺酸多纳非尼片、重组人凝血酶、盐酸吉卡昔替尼片、注射用重组人促甲状腺激素、盐酸吉卡昔替尼乳膏。","listedPrice":33.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泽璟制药,688266,泽璟制药股票,泽璟制药股票老虎,泽璟制药股票老虎国际,泽璟制药行情,泽璟制药股票行情,泽璟制药股价,泽璟制药股市,泽璟制药股票价格,泽璟制药股票交易,泽璟制药股票购买,泽璟制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泽璟制药(688266)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泽璟制药(688266)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}